Whiteside TL - Search Results

1

Shipping of therapeutic somatic cell products.

Whiteside TL, Griffin DL, Stanson J, Gooding W, McKenna D, Sumstad D, Kadidlo D, Gee A, Durett A, Lindblad R, Wood D, Styers D. Whiteside TL, et al. Cytotherapy. 2011 Feb;13(2):201-13. doi: 10.3109/14653249.2010.506507. Epub 2010 Aug 26. Cytotherapy. 2011. PMID: 20795760 Free PMC article.

2

Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial.

Ernstoff MS, Gooding W, Nair S, Bahnson RR, Miketic LM, Banner B, Day R, Whiteside T, Titus-Ernstoff L, Kirkwood JM. Ernstoff MS, et al. Cancer Res. 1992 Feb 15;52(4):851-6. Cancer Res. 1992. PMID: 1737346 Clinical Trial.

3

Preliminary trial of nonrecombinant interferon alpha in recurrent squamous cell carcinoma of the head and neck.

Vlock DR, Johnson J, Myers E, Day R, Gooding WE, Whiteside T, Pelch K, Sigler B, Wagner R, Colao D, et al. Vlock DR, et al. Head Neck. 1991 Jan-Feb;13(1):15-21. doi: 10.1002/hed.2880130103. Head Neck. 1991. PMID: 1989925

4

A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma.

Ernstoff MS, Nair S, Bahnson RR, Miketic LM, Banner B, Gooding W, Day R, Whiteside T, Hakala T, Kirkwood JM. Ernstoff MS, et al. J Clin Oncol. 1990 Oct;8(10):1637-49. doi: 10.1200/JCO.1990.8.10.1637. J Clin Oncol. 1990. PMID: 2120392

5

Constitutive production of IL-2 by human carcinoma cells, expression of IL-2 receptor, and tumor cell growth.

Lin WC, Yasumura S, Suminami Y, Sung MW, Nagashima S, Stanson J, Whiteside TL. Lin WC, et al. Among authors: whiteside tl. J Immunol. 1995 Nov 15;155(10):4805-16. J Immunol. 1995. PMID: 7594483

6

Increased expression of transforming growth factor-beta during chronic rejection.

Walgenbach KJ, Heeckt PF, Stanson JD, Whiteside TL, Bauer AJ. Walgenbach KJ, et al. Among authors: whiteside tl. Transplant Proc. 1996 Oct;28(5):2450. Transplant Proc. 1996. PMID: 8907892 No abstract available.

7

Increased presence of mast cells and interleukin-4 during chronic rejection of rat intestinal allografts.

Walgenbach KJ, Heeckt PF, Stanson JD, Whiteside TL, Bauer AJ. Walgenbach KJ, et al. Among authors: whiteside tl. Transplant Proc. 1996 Oct;28(5):2454. Transplant Proc. 1996. PMID: 8907896 No abstract available.

8

Biologic response modulation by tumor necrosis factor alpha (TNF alpha) in a phase Ib trial in cancer patients.

Logan TF, Gooding WE, Whiteside TL, Ernstoff MS, Kaplan SS, Miketic L, Vlock DR, Tompkins C, Wood DL, Nadler PI, Kirkwood JM. Logan TF, et al. Among authors: whiteside tl. J Immunother. 1997 Sep;20(5):387-98. doi: 10.1097/00002371-199709000-00008. J Immunother. 1997. PMID: 9336746 Clinical Trial.

9

Molecular analysis of the IL-2 receptor beta chain gene expressed in human tumor cells.

Suminami Y, Kashii Y, Law JC, Lin WC, Stanson J, Reichert TE, Rabinowich H, Whiteside TL. Suminami Y, et al. Among authors: whiteside tl. Oncogene. 1998 Mar 12;16(10):1309-17. doi: 10.1038/sj.onc.1201640. Oncogene. 1998. PMID: 9546432

10

Endogenous IL-2 in cancer cells: a marker of cellular proliferation.

Reichert TE, Watkins S, Stanson J, Johnson JT, Whiteside TL. Reichert TE, et al. Among authors: whiteside tl. J Histochem Cytochem. 1998 May;46(5):603-11. doi: 10.1177/002215549804600506. J Histochem Cytochem. 1998. PMID: 9562569

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

714 results

Search Page

Filters